Argus
•
May 13, 2026
AMRX: Lowering target price to $13.00
Summary
AMNEAL PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $13.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
AMPH: What does Argus have to say about AMPH?
Jul 01, 2026
•
AMPH
PTGX: Raising target price to $129.00
Jul 01, 2026
•
PTGX
COLL: Raising target price to $34.00
Jul 01, 2026
•
COLL
RCUS: Raising target price to $32.00
Jul 01, 2026
•
RCUS
AMPH: What does Argus have to say about AMPH?
Jun 24, 2026
•
AMPH
